SRA International, Inc. to Acquire Constella Group, LLC
SRA International, Inc. to Acquire Constella Group, LLC
FAIRFAX, VA, June 20, 2007-SRA International, Inc. (NYSE: SRX), a leading provider of technology and strategic consulting services and solutions to federal government organizations, today announced the signing of a definitive agreement to acquire Constella Group, LLC, a privately-held provider of global health consulting services.
Headquartered in Durham, NC, Constella employs more than 1500 professionals organized by three interrelated service offerings: domestic health sciences, international health development, and global drug development. The domestic health sciences business provides research, technology, communications, and strategy support to U.S. government agencies charged with protecting and advancing the health of their constituents. Constella’s international health development business helps emerging nations across the world create and implement health policy, primarily through contracts with the governments of the U.S. and the United Kingdom. The global drug development business provides blue-chip pharmaceutical, biotechnology, and medical device firms with the strategic insight and services needed to take a drug, biologic or device through the development process from concept to market. The company’s combination of capabilities, domain expertise, and geographic reach enable it to offer differentiated solutions to address the world’s most complex health issues. Constella acquired two companies during calendar year 2006. Excluding pre-acquisition revenue for those two companies, Constella revenue for calendar year 2006 was approximately $169 million.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
